drugset / Trial / NCT02595138

Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

NCT02595138

RandomizedParallel-groupOpen-labelTreatment

Summary

Triple-negative breast cancer is a special type of breast cancer with poor prgnosis and limited choices. Chemotherapy is the only choice of adjuvant systemic treatment options. Previous study suggested that zoledronic acid might have anti-tumor effect by eliminating the number of DTCs(Disseminated Tumor Cell )and had been proved to be effective as adjvant therapy in postmenopausal women whose breast cancer was Homonal receptor positive and who were receiving aromatase inhibitors. So it might be able to improve the survival of triple negative breast cancer patients.

Timeline

Start
2015-10
Primary completion
2018-10
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified